Alison Bauerlein net worth and biography

Alison Bauerlein Biography and Net Worth

CFO of Sight Sciences

Mrs. Bauerlein was appointed Chief Operating Officer of Sight Sciences effective November 2025, prior to which she served as Sight Sciences’ Chief Financial Officer since joining the Company in April 2023.

She brings experience leading global finance and accounting functions, including revenue management, reporting, investor relations and business development. She joined Sight Sciences from Inogen, a medical technology company offering innovative respiratory products for use in the homecare setting. She cofounded Inogen in 2001 and served as its Chief Financial Officer from 2009 through 2021, as Inogen scaled from start-up operations to over $350 million in annual sales. She also serves as member of the board of directors of Koya Medical since January 2021 and Balance Ophthalmics since July 2024. She received a B.A. in economics/mathematics with high honors from the University of California, Santa Barbara.

What is Alison Bauerlein's net worth?: The estimated net worth of Alison Bauerlein is at least $2.07 million as of October 1st, 2024. Ms. Bauerlein owns 392,555 shares of Sight Sciences stock worth more than $2,073,868 as of May 7th. This net worth estimate does not reflect any other investments that Ms. Bauerlein may own. Learn More about Alison Bauerlein's net worth.
How do I contact Alison Bauerlein?: The corporate mailing address for Ms. Bauerlein and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected]. Learn More on Alison Bauerlein's contact information.
Has Alison Bauerlein been buying or selling shares of Sight Sciences?: Alison Bauerlein has not been actively trading shares of Sight Sciences within the last three months. Most recently, Alison Bauerlein sold 10,130 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.08, for a transaction totalling $61,590.40. Following the completion of the sale, the chief financial officer now directly owns 392,555 shares of the company's stock, valued at $2,386,734.40. Learn More on Alison Bauerlein's trading history.
Who are Sight Sciences' active insiders?: Sight Sciences' insider roster includes Alison Bauerlein (CFO), Staffan Encrantz (Director), and Jesse Selnick (CFO). Learn More on Sight Sciences' active insiders.
Are insiders buying or selling shares of Sight Sciences?: In the last year, insiders at the sold shares 30 times. They sold a total of 307,648 shares worth more than $1,746,086.49. The most recent insider tranaction occured on April, 6th when CFO James Rodberg sold 7,231 shares worth more than $25,670.05. Insiders at Sight Sciences own 30.9% of the company. Learn More about insider trades at Sight Sciences.
Information on this page was last updated on 4/6/2026.

Alison Bauerlein Insider Trading History at Sight Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2024	Sell	10,130	$6.08	$61,590.40	392,555
7/2/2024	Sell	10,497	$6.21	$65,186.37	402,685
5/17/2024	Sell	13,066	$5.42	$70,817.72	413,182
4/3/2024	Sell	10,123	$5.08	$51,424.84	426,248

Alison Bauerlein Buying and Selling Activity at Sight Sciences

Sight Sciences Company Overview

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Today's Range

Now: $5.36

$4.36

$5.40

50 Day Range

MA: $4.07

$3.45

$5.62

2 Week Range

Now: $5.36

$2.81

$9.24

Volume

300,522 shs

Average Volume

317,056 shs

Market Capitalization

$291.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38